KR20210121045A - 항-ctla-4 결합 단백질 및 이의 사용 방법 - Google Patents

항-ctla-4 결합 단백질 및 이의 사용 방법 Download PDF

Info

Publication number
KR20210121045A
KR20210121045A KR1020217023740A KR20217023740A KR20210121045A KR 20210121045 A KR20210121045 A KR 20210121045A KR 1020217023740 A KR1020217023740 A KR 1020217023740A KR 20217023740 A KR20217023740 A KR 20217023740A KR 20210121045 A KR20210121045 A KR 20210121045A
Authority
KR
South Korea
Prior art keywords
seq
cdr3
cdr1
cdr2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217023740A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 스콧 존슨
아담 슐츠 아들러
레나 아비바 미즈라히
웅 웨언 임
미카엘 아센시오
에리카 린 스톤
Original Assignee
기가젠, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 기가젠, 인코포레이티드 filed Critical 기가젠, 인코포레이티드
Publication of KR20210121045A publication Critical patent/KR20210121045A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020217023740A 2018-12-27 2019-12-27 항-ctla-4 결합 단백질 및 이의 사용 방법 Pending KR20210121045A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785659P 2018-12-27 2018-12-27
US62/785,659 2018-12-27
PCT/US2019/068820 WO2020140084A1 (en) 2018-12-27 2019-12-27 Anti-ctla-4 binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20210121045A true KR20210121045A (ko) 2021-10-07

Family

ID=71126610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217023740A Pending KR20210121045A (ko) 2018-12-27 2019-12-27 항-ctla-4 결합 단백질 및 이의 사용 방법

Country Status (12)

Country Link
US (1) US12421311B2 (https=)
EP (1) EP3902821A4 (https=)
JP (3) JP7558949B2 (https=)
KR (1) KR20210121045A (https=)
CN (2) CN114008071B (https=)
AU (2) AU2019413366B2 (https=)
BR (1) BR112021012588A2 (https=)
CA (2) CA3124961C (https=)
IL (2) IL316757A (https=)
MX (1) MX2021007848A (https=)
SG (1) SG11202106764YA (https=)
WO (1) WO2020140084A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100230T1 (it) * 2015-10-23 2021-07-12 Fundacio Inst De Recerca Biomedica Irb Barcelona Molecole di legame che inibiscono la crescita tumorale
SG11202106764YA (en) 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
KR20230033719A (ko) * 2020-07-02 2023-03-08 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법
TW202235434A (zh) * 2020-12-31 2022-09-16 美商諾瓦拉克生物醫療有限公司 針對tnfr2之抗體及其用途
WO2023279068A1 (en) * 2021-07-02 2023-01-05 Gigagen, Inc. Anti-ctla-4 binding proteins and methods of use thereof
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US20110166335A1 (en) 2000-06-30 2011-07-07 Corbin David R Xenorhabdus sp. genome sequences and uses thereof
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US20090252741A1 (en) 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
EP3508215A3 (en) * 2012-12-03 2019-10-02 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
WO2015092393A2 (en) 2013-12-17 2015-06-25 Kymab Limited Human targets
PE20170441A1 (es) * 2014-06-06 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos
EP3256165B1 (en) 2015-02-13 2021-07-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
KR20250004095A (ko) 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
MA53355A (fr) * 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
ES2979210T3 (es) 2015-12-15 2024-09-24 Oncoc4 Inc Anticuerpos monoclonales anti-CTLA4 humano quiméricos y humanizados y usos de los mismos
SG10201603721TA (en) * 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
NL2017270B1 (en) * 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
CA3177692A1 (en) 2017-02-27 2018-08-30 Dragonfly Therapeutics, Inc. Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2
JP7173993B2 (ja) * 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
SG11202106764YA (en) 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
KR20230033719A (ko) 2020-07-02 2023-03-08 기가젠, 인코포레이티드 항-ctla-4 결합 단백질 및 이의 사용 방법

Also Published As

Publication number Publication date
CA3249127A1 (en) 2026-03-02
JP2025128343A (ja) 2025-09-02
IL316757A (en) 2025-01-01
JP7558949B2 (ja) 2024-10-01
JP2024042072A (ja) 2024-03-27
CN114008071A (zh) 2022-02-01
US12421311B2 (en) 2025-09-23
CA3124961C (en) 2025-11-25
AU2019413366B2 (en) 2025-06-05
WO2020140084A1 (en) 2020-07-02
CA3124961A1 (en) 2020-07-02
AU2025223772A1 (en) 2025-09-18
IL284156A (en) 2021-08-31
JP7854093B2 (ja) 2026-04-30
US20220064303A1 (en) 2022-03-03
MX2021007848A (es) 2021-10-26
BR112021012588A2 (pt) 2021-09-08
EP3902821A4 (en) 2022-11-30
CN114008071B (zh) 2025-01-21
IL284156B2 (en) 2025-04-01
JP7745669B2 (ja) 2025-09-29
EP3902821A1 (en) 2021-11-03
IL284156B1 (en) 2024-12-01
JP2022516071A (ja) 2022-02-24
SG11202106764YA (en) 2021-07-29
CN119930820A (zh) 2025-05-06
AU2019413366A1 (en) 2021-08-12

Similar Documents

Publication Publication Date Title
JP7745669B2 (ja) 抗ｃｔｌａ－４結合タンパク質およびその使用方法
KR20210121046A (ko) 항-pd-1 결합 단백질 및 이의 사용 방법
WO2020140094A1 (en) Anti-b7-h3 binding proteins and methods of use thereof
JP7783840B2 (ja) 抗ｃｔｌａ－４結合タンパク質及びその使用方法
WO2020142626A1 (en) Anti-ox40 binding proteins and methods of use thereof
WO2022006555A2 (en) BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
KR20210121047A (ko) 항-pd-l1 결합 단백질 및 이의 사용 방법
WO2020140070A1 (en) Anti-b7-h4 binding proteins and methods of use thereof
KR20240028506A (ko) 항-ctla-4 결합 단백질 및 이의 사용 방법
US20260125474A1 (en) Anti-CTLA-4 Binding Proteins and Methods of Use Thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701